

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
24th April 2025

Company:	Chordia Therapeutics Inc.
Representative:	Chief Executive Officer Hiroshi Miyake (Security Code: 190A TSE Growth Market)
Contact:	IR Representative Ami Kira

**Notice of Release of Transcript of Interim Financial Results Briefing for
the Fiscal Year Ending August 31, 2025**

Kanagawa Japan

24th April 2025 – Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; Chief Executive Officer: Hiroshi Miyake) held a “Briefing on interim financial results for the fiscal year ending August 31, 2025” on Friday, April 11, 2025, and the transcript of the event (including the Q&A session) has been published on Logmi Finance and our website.

We believe that this will help to bridge the information gap between investors and the company and lead to a deeper understanding of our business, and we will continue to strive for fair information disclosure.

1. Overview

Date : Friday, April 11, 2025, 15:30 - 16:30 (JST)
Presenter : Hiroshi Miyake, Chief Executive Officer
Method of holding : Web-based

2. Transcript article URL

<https://www.chorditherapeutics.com/en/ir/library/result.html>

About Chordia Therapeutics

Chordia’s lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors. For more information, please contact our website <https://www.chorditherapeutics.com/en/>.